Wang Y B, Xu O, Zhang R J, Shan C G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Mar 20;31(6):482-486. doi: 10.13201/j.issn.1001-1781.2017.06.018.
Glucose is a major metabolic substrate required for cancer cell survival and growth.Instead, the entry of glucose molecules into the cells is effected by a large family of structurally related transport proteins known as glucose transporters. Two main types of glucose transporters have been identified, namely, the passive facilitative glucose transporters(GLUTs) and the secondary active sodium-coupled glucose transporters(SGLTs).However, tumor cells may adapt to an ischemic microenvironment by upregulation of SGLTs in the plasma membrane which supplies the tumor cell with glucose even at very low extracellular glucose concentration.Therefore, SGLTs is essential for ischemic and hypoxic tumor cells to uptake glucose.Current research indicates that SGLTs may become a promising biomarker for cancer therapy.
葡萄糖是癌细胞存活和生长所需的主要代谢底物。相反,葡萄糖分子进入细胞是由一大类结构相关的转运蛋白介导的,这类蛋白被称为葡萄糖转运体。已鉴定出两种主要类型的葡萄糖转运体,即被动易化葡萄糖转运体(GLUTs)和继发性主动钠偶联葡萄糖转运体(SGLTs)。然而,肿瘤细胞可通过上调质膜上的SGLTs来适应缺血微环境,即使在细胞外葡萄糖浓度非常低的情况下,SGLTs也能为肿瘤细胞提供葡萄糖。因此,SGLTs对于缺血和缺氧肿瘤细胞摄取葡萄糖至关重要。目前的研究表明,SGLTs可能成为癌症治疗中一个有前景的生物标志物。